Sanofi responds to NICE negative FAD of olipudase alfa

Contributed by: PR Newswire

Tags

Sanofi-NICE-olipudase

More Like This

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

PR Newswire associated0

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

BioArctic receives Orphan Drug Designation for exidavnemab the US

Business Wire logo

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Business Wire logo

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

Hansa Biopharma Year-end report January-December 2023